Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-2206 in Advanced Gastric and GEJ Cancer
NCT01260701Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jan 2011
- Primary completion
- May 2014
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of MK-2206 in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by National Cancer Institute. Started Jan 2011; status: completed.
02
Drugs
MK-2206
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT01260701.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01260701.